Dhar Amrit, Mir Hyder, Koul Parvaiz A
Department of Internal and Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, IND.
Cureus. 2022 Jul 9;14(7):e26704. doi: 10.7759/cureus.26704. eCollection 2022 Jul.
Introduction The role of vitamin D deficiency in increasing susceptibility or modifying outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) illness is unclear, and data about the association is scant in low- and middle-income countries. We set out to investigate any correlation between baseline vitamin D status and the length of hospital stay in laboratory-confirmed SARS-CoV-2 patients in India. Methods Two hundred patients with SARS-CoV-2 infection requiring admission in a North Indian 1200-bedded tertiary care hospital were recruited prospectively from November 2020 to March 2021. Baseline serum 25 hydroxyvitamin D [25(OH)D] levels were measured within 24 hours of admission using chemiluminescent immunoassay. Patients were managed as per hospital management protocol for COVID-19. The primary outcome was the length of hospital stay; secondary outcomes were comparative clinical severity between two groups, rate of requirement of mechanical ventilation and/or non-invasive ventilation (NIV), and mortality. Vitamin D deficiency (VDD) was defined as baseline vitamin D levels of <30 ng/ml. Results Of the 200 recruited patients, 57.5% (n = 115) patients were vitamin D deficient, and the overall median length of hospital stay was around 12 days (IQR: 8-15 days). There was no statistically significant difference in the length of hospital stay between patients with normal serum vitamin D (VDS) and those with VDD, median LOS being 12 days (95% CI: 10, 12 days) in VDD cases and 11 days (95% CI: 10,13 days) in VDS cases (p = 0.176). No association between baseline 25(OH)D and any of the secondary outcomes could be established. Conclusions In Indian patients, baseline vitamin D levels are not associated with the length of hospital stay, need for mechanical ventilation, or mortality.
引言 维生素D缺乏在增加严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疾病易感性或改变其预后方面的作用尚不清楚，在低收入和中等收入国家，关于这种关联的数据也很少。我们着手调查印度实验室确诊的SARS-CoV-2患者的基线维生素D状态与住院时间之间的相关性。
方法 2020年11月至2021年3月，前瞻性招募了200名需要入住印度北部一家拥有1200张床位的三级护理医院的SARS-CoV-2感染患者。入院24小时内使用化学发光免疫分析法测量基线血清25羟维生素D [25(OH)D]水平。患者按照医院的COVID-19管理方案进行治疗。主要结局是住院时间；次要结局是两组之间的临床严重程度比较、机械通气和/或无创通气（NIV）需求率以及死亡率。维生素D缺乏（VDD）定义为基线维生素D水平<30 ng/ml。
结果 在招募的200名患者中，57.5%（n = 115）的患者维生素D缺乏，总体住院时间中位数约为12天（IQR：8 - 15天）。血清维生素D正常（VDS）患者和VDD患者的住院时间在统计学上没有显著差异，VDD病例的住院时间中位数为12天（95% CI：10, 12天），VDS病例为11天（95% CI：10, 13天）（p = 0.176）。基线25(OH)D与任何次要结局之间均未发现关联。
结论 在印度患者中，基线维生素D水平与住院时间、机械通气需求或死亡率无关。
